ABCG2 and diffuse large B-cell lymphoma: Previous research demonstrated that the abnormal expression levels of ABC transporters were associated with poor clinical outcomes of various malignancies, including high-risk DLBCL, but their overexpression does not appear to be consistently associated with treatment resistance in DLBCL [16,42,43,44].